Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDX NASDAQ:KALA NASDAQ:ONCY NASDAQ:PLRZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$1.66-2.4%$2.25$1.07▼$6.18$102.55M1.161.05 million shs709,660 shsKALAKALA BIO$3.09+1.0%$9.34$2.85▼$1,030.00$56.88M-2.2391,694 shs30,069 shsONCYOncolytics Biotech$0.87+0.2%$0.97$0.33▼$1.51$101.15M1.021.24 million shs749,441 shsPLRZPolyrizon$15.02-1.1%$13.46$2.88▼$18.20$28.42M-2.0458,175 shs68,590 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-2.35%-4.05%-7.26%-68.56%-23.50%KALAKALA BIO+0.98%-25.63%-72.63%-84.80%-98.11%ONCYOncolytics Biotech+0.22%-3.01%-14.42%-17.65%+68.51%PLRZPolyrizon-1.05%+6.22%+32.80%+8.45%-20.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$1.66-2.4%$2.25$1.07▼$6.18$102.55M1.161.05 million shs709,660 shsKALAKALA BIO$3.09+1.0%$9.34$2.85▼$1,030.00$56.88M-2.2391,694 shs30,069 shsONCYOncolytics Biotech$0.87+0.2%$0.97$0.33▼$1.51$101.15M1.021.24 million shs749,441 shsPLRZPolyrizon$15.02-1.1%$13.46$2.88▼$18.20$28.42M-2.0458,175 shs68,590 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-2.35%-4.05%-7.26%-68.56%-23.50%KALAKALA BIO+0.98%-25.63%-72.63%-84.80%-98.11%ONCYOncolytics Biotech+0.22%-3.01%-14.42%-17.65%+68.51%PLRZPolyrizon-1.05%+6.22%+32.80%+8.45%-20.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics 2.00Hold$5.50231.33% UpsideKALAKALA BIO 2.00Hold$1,018.7532,869.26% UpsideONCYOncolytics Biotech 2.60Moderate Buy$8.50873.77% UpsidePLRZPolyrizon 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest PLRZ, KALA, ONCY, and ALDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/4/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/24/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)3/27/2026KALAKALA BIO Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/18/2026ALDXAldeyra Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $2.003/17/2026ALDXAldeyra Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$0.70 per shareN/AKALAKALA BION/AN/AN/AN/A$35.58 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A($0.04) per shareN/APLRZPolyrizonN/AN/AN/AN/A$13.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$33.85M-$0.46N/AN/AN/AN/A-57.34%-36.33%N/AKALAKALA BIO-$26.98M-$166.50N/AN/AN/AN/A-12,971.16%-90.83%N/AONCYOncolytics Biotech-$28.76M-$0.29N/AN/AN/AN/A-2,185.97%-243.94%7/31/2026 (Estimated)PLRZPolyrizon-$3.34MN/AN/AN/AN/AN/AN/AN/AN/ALatest PLRZ, KALA, ONCY, and ALDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ONCYOncolytics Biotech-$0.05-$0.08-$0.03-$0.08N/AN/A5/7/2026Q1 2026ALDXAldeyra Therapeutics-$0.13-$0.06+$0.07-$0.06N/AN/A4/15/2026Q4 2025KALAKALA BIO-$8.50$43.00+$51.50$0.86N/AN/A3/31/2026Q4 2025ONCYOncolytics Biotech-$0.06-$0.08-$0.02-$0.08N/AN/A3/25/2026Q4 2025PLRZPolyrizonN/A$2.81N/A-$2.81N/AN/A2/27/2026Q4 2025ALDXAldeyra Therapeutics-$0.14-$0.1074+$0.0326-$0.10$24.25 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A2.722.72KALAKALA BION/A3.813.81ONCYOncolytics BiotechN/A1.121.12PLRZPolyrizonN/A29.0329.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%KALAKALA BIO24.61%ONCYOncolytics Biotech6.82%PLRZPolyrizonN/AInsider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics9.60%KALAKALA BIO2.24%ONCYOncolytics Biotech0.10%PLRZPolyrizonN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1060.32 million54.53 millionOptionableKALAKALA BIO3018.59 million18.17 millionNot OptionableONCYOncolytics Biotech30116.13 million116.01 millionNot OptionablePLRZPolyrizonN/A1.87 millionN/AN/APLRZ, KALA, ONCY, and ALDX HeadlinesRecent News About These CompaniesPolyrizon Secures First U.S. Clinical Site for NASARIX Allergy Blocker TrialMay 13 at 9:51 AM | tipranks.comPolyrizon Ltd. Signs Clinical Trial Agreement for NASARIXTM Allergy Blocker Study in TexasMay 13 at 9:30 AM | quiverquant.comQPolyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical TrialMay 13 at 9:25 AM | globenewswire.comPulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable ProtectionMay 11, 2026 | prnewswire.comPolyrizon Expands U.S. Patent Claims for Intranasal Drug Delivery PlatformMay 4, 2026 | tipranks.comPolyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery PlatformMay 4, 2026 | globenewswire.comPolyrizon Ltd. Files Divisional Patent Application for Advanced Trap & Target Intranasal Drug Delivery TechnologyApril 27, 2026 | quiverquant.comQPolyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery PlatformApril 27, 2026 | globenewswire.comPLRZ Share News TodayApril 19, 2026 | uk.investing.comPolyrizon Raises $3.5 Million via Registered Direct Offering and Private PlacementApril 14, 2026 | theglobeandmail.comPolyrizon Ltd. Ordinary Shares (PLRZ) Institutional HoldingsApril 8, 2026 | nasdaq.comPolyrizon Ltd. Completes $3.5 Million Registered Direct Offering and Private PlacementApril 8, 2026 | quiverquant.comQPolyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private PlacementsApril 8, 2026 | globenewswire.comPolyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private PlacementApril 7, 2026 | finance.yahoo.comPolyrizon Ltd. Ordinary Shares (PLRZ) Option ChainMarch 29, 2026 | nasdaq.comPolyrizon Ltd. Ordinary Shares (PLRZ) Insider ActivityMarch 28, 2026 | nasdaq.comPolyrizon Ltd.: Polyrizon Provides 2025 and Recent HighlightsMarch 26, 2026 | finanznachrichten.dePolyrizon Provides 2025 and Recent HighlightsMarch 26, 2026 | globenewswire.comPolyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025March 26, 2026 | markets.businessinsider.comPolyrizon Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025March 25, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimePLRZ, KALA, ONCY, and ALDX Company DescriptionsAldeyra Therapeutics NASDAQ:ALDX$1.66 -0.04 (-2.35%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$1.64 -0.02 (-1.45%) As of 08:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.KALA BIO NASDAQ:KALA$3.09 +0.03 (+0.98%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$3.08 -0.01 (-0.29%) As of 08:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Oncolytics Biotech NASDAQ:ONCY$0.87 +0.00 (+0.22%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$0.87 +0.00 (+0.13%) As of 07:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Polyrizon NASDAQ:PLRZ$15.02 -0.16 (-1.05%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$14.59 -0.43 (-2.86%) As of 07:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies 2 Ways to Play the Big Pharma Patent Cliff Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
